Oral anticoagulation and left atrial appendage closure in dialysis atrial fibrillation: between stroke prevention and...

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is common in dialysis patients, increasing stroke and mortality risk.
• Current guidelines lack clarity on oral anticoagulation (OAC) benefits in this population due to trial exclusions.
• Observational data on OAC efficacy and safety in dialysis AF patients are conflicting.

Purpose of the Study:

• To evaluate the net clinical benefit of oral anticoagulation (OAC) in dialysis patients with atrial fibrillation (AF).
• To review evidence supporting and opposing OAC and left atrial appendage closure (LAAC) for stroke prevention in this high-risk group.
• To emphasize the need for individualized decision-making and further randomized trials.

Main Methods:

• Review of existing cohort studies and randomized controlled trials (RCTs) on OAC (VKAs and DOACs) and LAAC in dialysis AF patients.
• Analysis of data regarding thromboembolic events, bleeding risks, and mortality.
• Synthesis of PRO and CON arguments regarding anticoagulation strategies.

Main Results:

• PRO argument: Selected high-risk patients may benefit from OAC or LAAC, with some studies showing reduced ischemic events and improved survival with OAC.
• CON argument: Large studies indicate no clear stroke reduction with warfarin and higher bleeding rates; DOAC trials show significant bleeding without clear efficacy gains.
• Emerging data suggest LAAC may offer stroke protection with lower bleeding and mortality compared to OAC or no prophylaxis.

Conclusions:

• The net clinical benefit of OAC in dialysis AF patients remains uncertain.
• Both OAC and LAAC are considered for thromboembolic prophylaxis in carefully selected patients.
• There is a consensus on the need for shared decision-making and large RCTs comparing OAC, LAAC, and no therapy in dialysis AF.